Detalhe da pesquisa
1.
Androgen receptor activity in T cells limits checkpoint blockade efficacy.
Nature
; 606(7915): 791-796, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35322234
2.
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
Br J Cancer
; 130(1): 73-81, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37951974
3.
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
N Engl J Med
; 378(15): 1408-1418, 2018 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29420164
4.
KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer.
Future Oncol
; 17(23): 3017-3026, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34044584
5.
The Relationship Between Checkpoint Inhibitors and the Gut Microbiome and Its Application in Prostate Cancer.
Oncology (Williston Park)
; 34(3)2020 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32212131
6.
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 19(10): 1404-1416, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30213449
7.
Gonadotropin-Releasing Hormone Antagonists in Prostate Cancer.
Oncology (Williston Park)
; 32(12): 599-602, 604-6, 2018 12 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-30632129
8.
Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlates.
Anticancer Drugs
; 28(1): 120-126, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27669423
9.
Cyclooxygenase-2 (COX-2) inhibition for prostate cancer chemoprevention: double-blind randomised study of pre-prostatectomy celecoxib or placebo.
BJU Int
; 119(5): 709-716, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27480340
10.
Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors.
Cancer
; 122(16): 2524-33, 2016 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27192055
11.
Treatment of Nonmetastatic Castration-Resistant Prostate Cancer.
Oncology (Williston Park)
; 30(4): 336-44, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-27085332
12.
A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer.
Invest New Drugs
; 33(2): 480-9, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25431127
13.
Interventions that may reduce depressive symptoms among prostate cancer patients: a systematic review and meta-analysis.
Psychooncology
; 24(12): 1686-93, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25753507
14.
Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer.
Oncology (Williston Park)
; 29(6): 416-23, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26091674
15.
Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized Treatment.
Am Soc Clin Oncol Educ Book
; 43: e390166, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37220335
16.
Evolution of structural rearrangements in prostate cancer intracranial metastases.
NPJ Precis Oncol
; 7(1): 91, 2023 Sep 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37704749
17.
Gender and Patient Satisfaction in a Veterans Health Administration Outpatient Chemotherapy Unit.
Fed Pract
; 39(Suppl 3): e0292, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36426107
18.
Composition of gastrointestinal microbiota in association with treatment response in individuals with metastatic castrate resistant prostate cancer progressing on enzalutamide and initiating treatment with anti-PD-1 (pembrolizumab).
Neoplasia
; 32: 100822, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35908379
19.
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
Eur Urol
; 81(2): 184-192, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34916086
20.
Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation Therapy.
Eur Urol Focus
; 8(4): 958-967, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34479838